179 related articles for article (PubMed ID: 11728003)
1. Virus population dynamics, fitness variations and the control of viral disease: an update.
Domingo E; Mas A; Yuste E; Pariente N; Sierra S; Gutiérrez-Riva M; Menéndez-Arias L
Prog Drug Res; 2001; 57():77-115. PubMed ID: 11728003
[TBL] [Abstract][Full Text] [Related]
2. Stealth nucleosides: mode of action and potential use in the treatment of viral diseases.
Daifuku R
BioDrugs; 2003; 17(3):169-77. PubMed ID: 12749753
[TBL] [Abstract][Full Text] [Related]
3. Quasispecies and the development of new antiviral strategies.
Domingo E
Prog Drug Res; 2003; 60():133-58. PubMed ID: 12790341
[TBL] [Abstract][Full Text] [Related]
4. Perspectives and opportunities for novel antiviral treatments targeting virus fitness.
Clementi M
Clin Microbiol Infect; 2008 Jul; 14(7):629-31. PubMed ID: 18190573
[TBL] [Abstract][Full Text] [Related]
5. Intra-host evolution of human immunodeficiency virus type 1 and viral fitness.
Clementi M; Canducci F; Bagnarelli P; Menzo S
New Microbiol; 2004 Apr; 27(2 Suppl 1):41-4. PubMed ID: 15646063
[TBL] [Abstract][Full Text] [Related]
6. [Viruses and antiviral drug resistance].
Hovi T; Järvinen A; Pyhälä R; Ristola M; Salminen M
Duodecim; 2002; 118(9):911-8. PubMed ID: 12238169
[No Abstract] [Full Text] [Related]
7. [Antiviral therapy: from influenza to Pfeiffer's disease].
Salzberger B
Internist (Berl); 2006 Dec; 47(12):1245-50. PubMed ID: 17009040
[TBL] [Abstract][Full Text] [Related]
8. Viral quasispecies evolution.
Domingo E; Sheldon J; Perales C
Microbiol Mol Biol Rev; 2012 Jun; 76(2):159-216. PubMed ID: 22688811
[TBL] [Abstract][Full Text] [Related]
9. Perspectives on antiviral drug development.
Wainberg MA
Antiviral Res; 2009 Jan; 81(1):1-5. PubMed ID: 18948140
[TBL] [Abstract][Full Text] [Related]
10. Viral error catastrophe by mutagenic nucleosides.
Anderson JP; Daifuku R; Loeb LA
Annu Rev Microbiol; 2004; 58():183-205. PubMed ID: 15487935
[TBL] [Abstract][Full Text] [Related]
11. Can modulation of viral fitness represent a target for anti-HIV-1 strategies?
Clementi M
New Microbiol; 2004 Jul; 27(3):207-14. PubMed ID: 15460522
[TBL] [Abstract][Full Text] [Related]
12. Novel activities of safe-in-human broad-spectrum antiviral agents.
Ianevski A; Zusinaite E; Kuivanen S; Strand M; Lysvand H; Teppor M; Kakkola L; Paavilainen H; Laajala M; Kallio-Kokko H; Valkonen M; Kantele A; Telling K; Lutsar I; Letjuka P; Metelitsa N; Oksenych V; Bjørås M; Nordbø SA; Dumpis U; Vitkauskiene A; Öhrmalm C; Bondeson K; Bergqvist A; Aittokallio T; Cox RJ; Evander M; Hukkanen V; Marjomaki V; Julkunen I; Vapalahti O; Tenson T; Merits A; Kainov D
Antiviral Res; 2018 Jun; 154():174-182. PubMed ID: 29698664
[TBL] [Abstract][Full Text] [Related]
13. Update of the drug resistance mutations in HIV-1: 2004.
Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
[No Abstract] [Full Text] [Related]
14. Short communication: transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals.
Treviño A; Soriano V; Madejon A; Rodriguez C; Barros C; Botecchia M; Tuma P; Del Romero J; de Mendoza C
AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1273-6. PubMed ID: 20001517
[TBL] [Abstract][Full Text] [Related]
15. Comparison of antiviral resistance across acute and chronic viral infections.
Mason S; Devincenzo JP; Toovey S; Wu JZ; Whitley RJ
Antiviral Res; 2018 Oct; 158():103-112. PubMed ID: 30086337
[TBL] [Abstract][Full Text] [Related]
16. Lamivudine for chronic hepatitis B and HIV co-infection.
Carton JA; Maradona JA; Asensi V; Rodríguez M; Martínez A
AIDS; 1999 May; 13(8):1002-3. PubMed ID: 10371189
[No Abstract] [Full Text] [Related]
17. [Prophylaxis and treatment of viral infections. Part II--infections caused by RNA viruses].
Strycharz M; Bartecka K; Polz-Dacewicz M
Pol Merkur Lekarski; 2005 Feb; 18(104):233-5. PubMed ID: 17877139
[TBL] [Abstract][Full Text] [Related]
18. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.
Locarnini S; Warner N
Antivir Ther; 2007; 12 Suppl 3():H15-23. PubMed ID: 18284179
[TBL] [Abstract][Full Text] [Related]
19. Sex differences in prophylaxis and therapeutic treatments for viral diseases.
Klein SL
Handb Exp Pharmacol; 2012; (214):499-522. PubMed ID: 23027464
[TBL] [Abstract][Full Text] [Related]
20. Pre-existence and emergence of drug resistance in a generalized model of intra-host viral dynamics.
Alexander HK; Bonhoeffer S
Epidemics; 2012 Dec; 4(4):187-202. PubMed ID: 23351371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
